Organon Docks Into India’s Family Planning Program, Makes Early Gains

Organon's commercial director and lead for the South Asia region, Anjan Sen, discusses with Scrip the prospects of contraceptive Implanon NXT with its inclusion in India’s historic family planning program. The Merck spin-out is also on course to debut its Jada System this year, opening up new growth avenues as it disentangles and builds out operations in the region.

Anjan Sen
Anjan Sen, Commercial Director And Lead for The South Asia Region, Organon • Source: Organon

Organon appears to have had impressive wins in India for its women’s health portfolio as the Merck & Co., Inc. spin-out propels its business and disentangles itself from the parent entity in the country.

While the inclusion of Organon’s sub-dermal long-acting reversible contraceptive Implanon NXT (sold as Nexplanon in the US) in India’s long-running...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip